First National Bank of Omaha Acquires 3,092 Shares of Stryker Corporation $SYK

First National Bank of Omaha raised its stake in shares of Stryker Corporation (NYSE:SYK) by 61.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,129 shares of the medical technology company’s stock after purchasing an additional 3,092 shares during the period. First National Bank of Omaha’s holdings in Stryker were worth $2,639,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Stryker during the fourth quarter worth about $1,822,272,000. Auto Owners Insurance Co boosted its holdings in Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP increased its position in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Corient Private Wealth LLC raised its holdings in Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Stryker by 241.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,555,638 shares of the medical technology company’s stock worth $511,167,000 after purchasing an additional 1,100,673 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 315,370 shares of company stock valued at $98,463,501. 4.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on SYK shares. Needham & Company LLC lowered their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Royal Bank Of Canada cut their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. BMO Capital Markets assumed coverage on shares of Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective on the stock. Finally, Citizens Jmp reduced their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Price Performance

Shares of NYSE SYK opened at $331.96 on Wednesday. The stock has a market cap of $127.33 billion, a price-to-earnings ratio of 34.40, a PEG ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The firm’s 50-day simple moving average is $325.56 and its 200 day simple moving average is $333.05.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.